Regeneron Pharmaceuticals (REGN) Receivables - Net (2009 - 2026)

Regeneron Pharmaceuticals has reported Receivables - Net for 18 years, with the latest figure at $5.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 3.06% year-over-year to $5.7 billion; the trailing twelve-month figure through Mar 2026 stood at $5.7 billion (up 3.06% YoY), and the FY2025 full-year result was $5.7 billion, down 7.58% from the prior year.
• Receivables - Net for Q1 2026 stood at $5.7 billion, roughly flat from $5.7 billion in the prior quarter.
• The five-year high for Receivables - Net was $6.2 billion in Q4 2024, with the low at $4.8 billion in Q1 2022.
• Average Receivables - Net over 5 years is $5.5 billion, with a median of $5.6 billion recorded in 2023.
• Peak annual rise in Receivables - Net reached 15.96% in 2022, while the deepest fall reached 26.25% in 2022.
• Tracing REGN's Receivables - Net over 5 years: stood at $5.3 billion in 2022, then climbed by 6.35% to $5.7 billion in 2023, then rose by 9.61% to $6.2 billion in 2024, then slipped by 7.58% to $5.7 billion in 2025, then slipped by 0.18% to $5.7 billion in 2026.
• The last three Receivables - Net figures came in at $5.7 billion (Q1 2026), $5.7 billion (Q4 2025), and $5.7 billion (Q3 2025), per Business Quant data.

Peer Comparison